Differential effects of d-sotalol on subendocardial Purkinje myocytes isolated from normal or 10 to 14 days postinfarction canine hearts: Role of extracellular potassium concentration

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 2, 1998, Pages 274-283

  Marschang, Harald ^a,b   Schöls, Wolfgang ^a   Karolyi, Laszlo ^a   Beyer, Thorsten ^a   Kübier, Wolfgang ^a   Brachmann, Johannes ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Action potentials; D Sotalol; Myocardial infarction; Potassium; Purkinje cells

Indexed keywords

ANTIARRHYTHMIC AGENT; POTASSIUM ION; SOTALOL;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG SENSITIVITY; ENDOCARDIUM; HEART INFARCTION; MICROELECTRODE; NONHUMAN; PRIORITY JOURNAL; PURKINJE CELL;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CELLS, CULTURED; DOGS; HEART; MYOCARDIAL INFARCTION; MYOCARDIUM; POTASSIUM; PURKINJE FIBERS; SOTALOL;

EID: 0344878842     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199808000-00015     Document Type: Article

References (38)

1. Friedman PL, Fenoglio JJ, Wit AL. Time course for reversal of electrophysiological and ultrastructural abnormalities in subendocardial Purkinje fibers surviving extensive myocardial infarction in dogs. Circ Res 1975;36(1):127-44.
2. Lazzara R, El-Sherif N, Scherlag JB. Early and late effects of coronary artery occlusion on canine Purkinje fibers. Circ Res 1974;35(3): 391-9.
3. Beyer T, Montero M, Brachmann J, Kübler W. Differential effects of propafenone on normal and infarcted canine endocardial layers. J Cardiovasc Pharmacol 1994;23:378-86.
4. Gardner PI, Ursell PC, Fenoglio JJ, Wit AL. Electrophysiologic and anatomic basis for fractionated electrograms from healed myocardial infarcts. Circulation 1985;72(3):596-611.
5. Sugi K, Karagueuzian HS, Fishbein MC, Mandel WJ, Peter T. Cellular electrophysiologic characteristics of surviving subendocardial fibers in chronically infarcted right ventricular myocardium susceptible to inducible sustained ventricular tachycardia. Am Heart J 1987;114(3):559-69.
6. Ursell PC, Gardner PI, Albala A, Fenoglio JJ, Wit AL. Structural and electrophysiological changes in the epicardial border zone of canine myocardial infarcts during infarct healing. Circ Res 1985;56(3): 436-51.
7. Patterson E, Scherlag BJ, Lazzara R. Rapid inward current in ischemically injured subepicardial myocytes bordering myocardial infarction. J Cardiovasc Electrophysiol 1993;4(1):9-22.
8. max and the transient outward current. Circulation 1992;85(3):1175-88.
9. Lukas A, Antzelevitch C. Differences in the electrophysiological response of canine ventricular epicardium and endocardium to ischemia: role of the transient outward current. Circulation 1993;88(6):2903-15.
10. Litovsky SH, Antzelevitch C. Transient outward current prominent in canine ventricular epicardium but not endocardium. Circ Res 1988;62(1):116-26.
11. Hondeghem LM, Cotner CL. Reproducible and uniform cardiac ischemia: effects of antiarrhythmic drugs. Am J Physiol 1978;235(5): H574-80.
12. Hondeghem LM. Effects of lidocaine, phenytoin, and quinidine on the ischemic canine myocardium. J Electrocardiol 1976;9(3):204-9.
13. Kupersmith J, Antman EM, Hoffman BF. In vivo electrophysiological effects of lidocaine in canine acute myocardial infarction. Circ Res 1975;36(1):84-91.
14. Cobbe SM. Modification of class III antiarrhythmic activity in abnormal myocardium. Cardiovasc Res 1988;22(12):847-54.
15. Cobbe SM, Manley BS, Alexopoulos D. The influence of acute myocardial ischemia on the class III antiarrhythmic action of sotalol. Cardiovasc Res 1985;19(11):661-7.
16. Brachmann J, Senges J, Gao T-L. Class III effects of sotalol are dependent on the extracellular potassium concentration in normal and depressed fibers following myocardial infarction [Abstract]. J Am Coll Cardiol 1984;2:617.
17. Boyden PA, Albala A, Dresdner KP Jr. Electrophysiology and ultra-structure of canine subendocardial Purkinje cells isolated from control and 24-hour infarcted hearts. Circ Res 1989;65(4):955-70.
18. Jeck C, Pinto J, Boyden P. Transient outward currents in subendocardial Purkinje myocytes surviving in the infarcted heart. Circulation 1995;92(3):465-73.
19. Wit AL, Janse MJ. Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction. Circulation 1992;85(suppl 1):132-42.
20. Scherlag BJ, Kabell G, Brachmann J, Harrison L, Lazzara R. Mechanisms of spontaneous and induced ventricular arrhythmias in the 24-hour infarcted dog heart. Am J Cardiol 1983;51(1):207-13.
21. Lazzara R, Scherlag BJ. Generation of arrhythmias in myocardial ischemia and infarction. Am J Cardiol 1988;61(2):20-6A.
22. Friedman PL, Steward JR, Fenoglio JJ Jr, Wit AL. Survival of subendocardial Purkinje fibers after extensive myocardial infarction in dogs: in vitro and in vivo correlation. Circ Res 1973;33(6):597-611.
23. Wit AL, Janse MJ. Experimental models of ventricular tachycardia and fibrillation caused by ischemia and infarction. Circulation 1992;85(suppl 1):132-42.
24. Lazzara R. Antiarrhythmic drugs and torsades de pointes. Eur Heart J 1993;14(suppl H):88-92.
25. Roden DM. Early after-depolarizations and torsades de pointes: implications for the control of cardiac arrhythmias by prolonging repolarization. Eur Heart J 1993;14(suppl H):56-61.
26. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81(2):686-90.
27. Schmitt C, Beyer T, Karch M, et al. Sotalol exhibits reverse use dependent action on monophasic action potentials in normal but not in infarcted canine ventricular myocardium. J Cardiovasc Pharmacol 1992;19(4):487-92.
28. Freigang KD, Bauer A, Becker R, et al. Differential effects of d-sotalol on normal and infarcted myocardium: an experimental study using epicardial mapping. J Cardiovasc Res 1997;35:52-9.
29. Singh BN. Expanding clinical role of unique class III antiarrhythmic effects of sotalol. Am J Cardiol 1990;65(2):84-8A.
30. Brachmann J, Beyer T, Schmitt C, et al. Electrophysiologic and antiarrhythmic effects of d-sotalol. J Cardiovasc Pharmacol 1992; 20(suppl 2):S91-5.
31. Brachmann J, Schöls W, Beyer T, Montera M, Enders B, Kübler W. Acute and chronic antiarrhythmic efficacy of d-sotalol in patients with sustained ventricular tachyarrhythmias. Eur Heart J 1993; 14(suppl H):85-7.
32. Cobbe SM, Manley BS. Effects of elevated extracellular potassium concentrations on the class III antiarrhythmic action of sotalol. Cardiovasc Res 1985;19(2):69-75.
33. Hafner D, Berger F, Borchard U, Kullman A, Scherlitz A. Electrophysiological characterization of the class III activity of sotalol and its enantiomers. Arzneimittelforschung/Drug Res 1988;38(2):231-6.
34. Yang T, Tande PM, Lathrop DA, Refsum H. Effects of altered extra-cellular potassium and pacing cycle length on the class III antiar-rhythmic actions of dofetilide (UK-68,798) in guinea pig papillary muscle. Cardiovasc Drugs Ther 1992;6(4):429-36.
35. Wettwer W, Scholtysik G, Schaad A, Himmel H, Ravens U. Effects of the new class III antiarrhythmic drug E-4031 on myocardial contractility and electrophysiological parameters. J Cardiovasc Pharmacol 1991;17(3):480-7.
36. r blockers dofetilide, d-sotalol, E-4031 and MK-499. J Cardiovasc Pharmacol 1994;24(2):199-208.
37. Echt DS, Liebson PR, Mitchel EB. Mortality and morbidity in patients receiving encainide, flecainide or placebo: the Cardiac Arrhythmia suppression Trial (CAST). N Engl J Med 1991;324(12): 781-8.
38. Waldo AL, Camm AJ, deRuyter H. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). Am J Cardiol 1995;75(15):1023-7.